MRTXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (23 1月 2024 @ 06:00):

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States...

Stats
本日の出来高	20.96M
平均出来高	1.78M
時価総額	4.12B
EPS	$0 ( 2024-02-27 )
次の収益日	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.82
ATR14	$0.485 (0.83%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Boxer Capital, Llc	Sell	30 518	Common Stock
2024-01-23	Boxer Capital, Llc	Sell	1 413 475	Warrant (right to purchase)
2024-01-23	Sharp Shalini	Sell	4 162	Common Stock
2024-01-23	Sharp Shalini	Sell	5 252	Common Stock
2024-01-23	Sharp Shalini	Sell	6 808	Common Stock

INSIDER POWER
-93.85
Last 100 transactions
Buy: 125 442 \| Sell: 3 801 194

ボリューム相関

長: 0.17 (neutral)

短: -0.56 (weak negative)

Signal:(56.142) Neutral

Mirati Therapeutics Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Mirati Therapeutics Inc 相関 - 通貨/商品

-0.51
( weak negative )

0.39
( neutral )

0.23
( neutral )

-0.12
( neutral )

0.63
( weak )

0.68
( moderate )

Mirati Therapeutics Inc 財務諸表

Annual	2022
収益:	$12.44M
総利益:	$11.84M (95.18 %)
EPS:	$-13.18

FY	2022
収益:	$12.44M
総利益:	$11.84M (95.18 %)
EPS:	$-13.18

FY	2021
収益:	$72.09M
総利益:	$0.00 (0.00 %)
EPS:	$-11.21

FY	2020
収益:	$13.40M
総利益:	$0.00 (0.00 %)
EPS:	$-7.96

Financial Reports:

No articles found.

Mirati Therapeutics Inc

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.